Buchang Pharmaceutical's subsidiary gets clinical trial nod

Shandong Buchang Pharmaceutical Co., Ltd. [SSE:603858] announced that its holding subsidiary, Zhejiang Tianyuan Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its varicella vaccine. The varicella vaccine, a live attenuated virus vaccine, is intended for preventing varicella. As of February 28, 2025, the company has invested approximately RMB 28.55 million in the project. Several companies already manufacture varicella vaccines in China. The company cautioned investors regarding uncertainties inherent in pharmaceutical R&D and clinical trials and emphasized that the vaccine must be approved before it can be commercialized.